NDA 218784 · Servier
Voranigo
Vorasidenib · Oral · Isocitrate Dehydrogenase 1 Inhibitor; Isocitrate Dehydrogenase 2 Inhibitor
NovelBreakthrough therapyPriority reviewOrphanCDER novel approval, Aug 6, 2024: To treat Grade 2 astrocytoma or oligodendroglioma
Last checked: Nov 19, 2026Latest source record: Jun 10, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2024
Aug 6, 2024
Approved uses
1
Original approval plus efficacy supplements
Registered trials
22
5 Phase 3, 8 recruiting
FAERS reports
612
463 serious, 12 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jun 20, 2026.
VORANIGO is indicated for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible isocitrate dehydrogenase-1 (IDH1) or isocitrate dehydrogenase-2 (IDH2) mutation, as detected by an FDA-approved test, following surgery including biopsy, sub-total resection, or gross total resection [see Dosage and Administration (2.1) , Clinical Pharmacology (12.1) and Clinical Studies (14) ]. VORANIGO is an isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2) inhibitor indicated for the treatment of adult and pediatric patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation, as detected by an FDA-approved test, following surgery including biopsy, sub-total resection, or gross total resection. ( 1 )
Mechanism: Vorasidenib is a small molecule inhibitor that targets isocitrate dehydrogenase-1 and 2 (IDH1 and IDH2) enzymes. In vitro, vorasidenib inhibited the IDH1 wild type and mutant variants, including R132H and the IDH2 wild type and mutant variants. In cell-based and in vivo tumor models expressing IDH1 or IDH2 mutated proteins, vorasidenib decreased production of 2-hydroxyglutarate (2-HG) and partially restored cellular differentiation.
Therapeutic areas: Oncology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 6, 2024 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyOrphanLabelLetterReview
2 products under this application
- VORANIGO · VORASIDENIB 10MG · TABLET, ORAL · Prescription
- VORANIGO · VORASIDENIB 40MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Vorasidenib" as an intervention, any sponsor and status, largest first.
- A Phase 3, Multicenter Study of Vorasidenib in Combination With Temozolomide (TMZ) in Participants With IDH1- or IDH2 Mutant High-grade Astrocytoma.Pivotal-lookingNot yet recruiting
Institut de Recherches Internationales ServierAcademic, hospital or other
NCT07940946 · 550 participants (planned) · Start Mar 1, 2027 · Primary completion Nov 1, 2034
Drug: Vorasidenib; Placebo and 1 more · For: IDH-mutant High-grade Astrocytoma
- Vorasidenib Maintenance for IDH Mutant AstrocytomaPivotal-lookingRecruiting
European Organisation for Research and Treatment of Cancer - EORTCResearch network
NCT06809322 · 468 participants (planned) · Start Jan 16, 2026 · Primary completion Apr 13, 2035
Drug: Vorasidenib; Vorasidenib Placebo · For: IDH-mutant Grade 2 or 3 Astrocytoma
Sites: Bedford Park, Australia; Camperdown, Australia; Heidelberg, Australia · 59 sites in all
- Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain CancerPivotal-lookingRecruiting
Alliance for Clinical Trials in OncologyAcademic, hospital or other
NCT07215910 · 408 participants (planned) · Start Jun 24, 2026 · Primary completion May 31, 2033
Drug: Temozolomide; Vorasidenib and 1 more · For: Astrocytoma, IDH-Mutant, Grade 3
Sites: Phoenix, Arizona; Anaheim, California; Bakersfield, California · 177 sites in all
- Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO)Pivotal-lookingActive, not recruiting
Institut de Recherches Internationales ServierAcademic, hospital or other
NCT04164901 · 331 participants · Start Jan 5, 2020 · Primary completion Sep 6, 2022
Drug: Vorasidenib; Matching Placebo · For: Grade 2 Glioma; Residual Glioma; Recurrent Glioma
Sites: Birmingham, Alabama; Duarte, California; La Jolla, California · 84 sites in all
- Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 MutationsActive, not recruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT04603001 · 260 participants (planned) · Start Nov 19, 2020 · Primary completion Jul 3, 2023
Drug: LY3410738; Venetoclax and 1 more · For: Acute Myeloid Leukemia (AML); Myelodysplastic Syndrome (MDS); Chronic Myelomonocytic Leukemia (CMML) and 1 more
Sites: Duarte, California; Los Angeles, California; Sacramento, California · 37 sites in all
Servier Bio-Innovation LLCIndustry
NCT05843708 · 64 participants · Start Apr 14, 2023 · Primary completion Jul 28, 2023
Drug: Vorasidenib 40 mg Oral Tablet; Ciprofloxacin 500 mg Oral Tablet and 1 more · For: Healthy Subjects
Sites: Austin, Texas
Servier (Tianjin) Pharmaceutical Co. LTD.Industry
NCT06969352 · 62 participants · Start Sep 2, 2025 · Primary completion Apr 2028
Drug: Vorasidenib · For: Gliomas
Sites: Beijing, China; Qionghai, China; Chengdu, China
- Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant GliomaActive, not recruiting
Institut de Recherches Internationales ServierAcademic, hospital or other
NCT05484622 · 60 participants · Start Jan 20, 2023 · Primary completion Feb 12, 2026
Drug: Vorasidenib; Pembrolizumab · For: Astrocytoma; Oligodendroglioma
Sites: Birmingham, Alabama; Los Angeles, California; San Francisco, California · 17 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- alanine aminotransferase increased83
- aspartate aminotransferase increased68
- fatigue67
- malignant neoplasm progression46
- seizure41
- headache39
- nausea38
- hepatic cytolysis34
- hepatic enzyme increased34
- gamma-glutamyltransferase increased28
- liver function test increased24
- hepatotoxicity21
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2023 | 2 |
| 2024 | 42 |
| 2025 | 313 |
| 2026 | 255 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Voranigo (Vorasidenib Citrate)
2024 spending
$19.2M
Beneficiaries
201
495 claims
Per beneficiary
$95,729
$1,284.70 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $0 |
| 2024 | $19,241,447 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma.
Mellinghoff IK, van den Bent MJ, Blumenthal DT, et al. · N Engl J Med 2023 · Clinical Trial, Phase III, Randomized Controlled Trial
- Vorasidenib in IDH1-mutant or IDH2-mutant low-grade glioma (INDIGO): secondary and exploratory endpoints from a randomised, double-blind, placebo-controlled, phase 3 trial.
Cloughesy TF, van den Bent MJ, Touat M, et al. · Lancet Oncol 2025 · Clinical Trial, Phase III, Randomized Controlled Trial
- Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial.
Mellinghoff IK, Lu M, Wen PY, et al. · Nat Med 2023 · Clinical Trial, Phase I, Research Support, Non-U.S. Gov't
- Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial.
Mellinghoff IK, Penas-Prado M, Peters KB, et al. · Clin Cancer Res 2021 · Clinical Trial, Phase I, Research Support, N.I.H., Extramural
- Safety, efficacy, and PK/PD of vorasidenib in previously treated patients with mIDH1/2 hematologic malignancies: A phase 1 study.
DiNardo CD, De Botton S, Pollyea DA, et al. · Am J Hematol 2023 · Clinical Trial, Phase I, Research Support, Non-U.S. Gov't
- Unlocking therapeutic synergy: IDH inhibitors and immunotherapy combination in preclinical and clinical IDH mutant glioma models - A systematic review.
Ramadas M, Jacob N, Ameratunga M, et al. · J Clin Neurosci 2025 · Systematic Review
Sponsor: Servier
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.